Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 14/20 | 0.68 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.60 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.47 |
| ▸ | CDK2 | P24941 | 6/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCND1 | P24385 | 1/20 | 0.44 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.44 |
| ▸ | CCNH | P51946 | 1/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637715 | 0.83 | ROCK2 (0.88) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL21573606 | 0.82 | ROCK2 (0.65) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL16637609 | 0.81 | ROCK2 (1.00) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL16637615 | 0.81 | ROCK2 (0.77) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL20784061 | 0.79 | ROCK2 (0.65) | ROCK2ROCK1CCNE1CDK2CDK4 | |
| SCHEMBL20783858 | 0.76 | ROCK2 (0.57) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL21573527 | 0.76 | ROCK2 (0.64) | ROCK2ROCK1CCNE1CDK2 | |
| SCHEMBL16637773 | 0.75 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL24213275 | 0.75 | ROCK2 (0.40) | ROCK2ROCK1CCNE1CDK2CDK4 | |
| SCHEMBL20784021 | 0.74 | ROCK2 (0.57) | ROCK2ROCK1CCNE1CDK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055301-B1 | (2-(5-ISOINDOLIN-2-YL)PYRIMIDIN-4-YL)-AMINE DERIVATIVES AS RHO KINASE INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | KADMON CORP LLC (US) | 2019-11-20 | — | — | EP | disclosed |